Literature DB >> 17234759

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

Helen Morrison1, Tobias Sperka, Jan Manent, Marco Giovannini, Helmut Ponta, Peter Herrlich.   

Abstract

The small G-protein Ras is a tightly controlled regulator of cell fate. Prolonged or persistent arrest in the activated GTP-loaded state by mutation of Ras as in lung cancer or in a Ras-GTPase-activating protein as in neurofibromatosis type 1 promotes tumorigenesis. We now show that the tumor-suppressor protein merlin (mutated in neurofibromatosis type 2) also controls Ras activity. Systematic analysis of growth factor signaling located the step of merlin interference to the activation of Ras and Rac. Merlin independently uncouples both Ras and Rac from growth factor signals. In the case of Ras, merlin acts downstream of the receptor tyrosine kinase-growth factor receptor binding protein 2 (Grb2)-SOS complex. However, merlin does not bind either SOS or Ras, but it counteracts the ERM (ezrin, radixin, moesin)-dependent activation of Ras, which correlates with the formation of a complex comprising ERM proteins, Grb2, SOS, Ras, and filamentous actin. Because efficient signaling from Ras requires Rac-p21-activated kinase-dependent phosphorylations of Raf and mitogen-activated protein/extracellular signal-regulated kinase kinase, merlin can also inhibit signal transfer from dominantly active Ras mutants. We propose that the interference of merlin with Ras- and Rac-dependent signal transfer represents part of the tumor-suppressive action of merlin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234759     DOI: 10.1158/0008-5472.CAN-06-1608

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  Merlin's wizardry guides cohesive migration.

Authors:  Ansgar Zoch; Helen Morrison
Journal:  Nat Cell Biol       Date:  2015-03       Impact factor: 28.824

3.  Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length.

Authors:  Courtney Thaxton; Marga Bott; Barbara Walker; Nicklaus A Sparrow; Stephen Lambert; Cristina Fernandez-Valle
Journal:  Mol Cell Neurosci       Date:  2010-12-21       Impact factor: 4.314

Review 4.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 5.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

6.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.

Authors:  Alizée Boin; Anne Couvelard; Christophe Couderc; Isabel Brito; Dan Filipescu; Michel Kalamarides; Pierre Bedossa; Leanne De Koning; Carine Danelsky; Thierry Dubois; Philippe Hupé; Daniel Louvard; Dominique Lallemand
Journal:  Neuro Oncol       Date:  2014-02-20       Impact factor: 12.300

7.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

10.  The phosphorylation status of merlin in sporadic vestibular Schwannomas.

Authors:  Zhaoyan Wang; Yanjun Lu; Juanjuan Tang; Haojie Wang; Hao Wu
Journal:  Mol Cell Biochem       Date:  2009-01-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.